Novartis opens new radioligand therapy manufacturing facility

Swiss pharma giant Novartis (NOVN: VX) announced the opening of a new 10,000-square-foot radioligand therapy (RLT) manufacturing facility in Carlsbad, California, USA.

This state-of-the-art site represents a key milestone in the company’s previously announced $23 billion investment in USA infrastructure over the next five years, the company noted.

The opening of the Carlsbad manufacturing facility allows Novartis to seamlessly meet future demand for RLT, adding additional capacity and augmenting the company’s world-class supply chain capabilities. The Carlsbad facility has been filed with the FDA as an additional US point of supply, and commercial manufacturing may begin once approval is granted.